We’re changing the shape of cataract surgery.

Be part of the transformation.

The Light Adjustable Lens™ (LAL®) is the first and only lens that can be adjusted in the eye, after cataract surgery. Precise UV light treatments adjust the shape of the Light Adjustable Lens, giving your patients truly custom vision that is literally transformative. Imagine what the LAL could do for your practice.

How the Light Adjustable Lens Is Different

The Light Adjustable Lens has revolutionized cataract surgery moving the important decisions about final lens power to its ideal place: after surgery. This way, the process can be more precise than ever, accounting for lens shift and refractive changes during the healing process, to achieve the best possible outcome.

We know the Light Adjustable Lens is a switch from the usual method of choosing from pre-manufactured lens powers before surgery to hit your patients’ post-surgery targets. To support this switch, the accuracy of the Light Adjustable Lens has been documented in clinical studies.

The LAL corrects down to 0.5 diopters of astigmatism, which is the lowest level approved to be treated.
The LAL offers LASIK-like accuracy in cataract surgery.
The LAL provides optimized vision for patient satisfaction.
“The Light Adjustable Lens has excellent accuracy and quality of vision. We are able to adjust the lens post-operatively to optimize our patients’ vision. We love the lens almost as much as our patients.”
Stephen Slade, MD
Stephen Slade, MDSlade & Baker Vision
“We were nervous making this investment in our current economic climate, but it was a great decision. We returned our investment in under five months, which allowed us to generate enough revenue to give generous wage increases to our staff.”
Marianne Sloan, MBA
Marianne Sloan, MBAFour Corners Eye Clinic
“My ‘aha!’ moment was when I realized the joy the Light Adjustable Lens brings to our practice. Patients, staff, and surgeons are all so excited about the results. We even ring a bell to celebrate when a patient has their final light treatment.”
Deborah Gess Ristvedt, DO
Deborah Gess Ristvedt, DOVance Thompson Vision
“The Light Adjustable Lens has been a game changer in my practice. The visual quality and accuracy of the results are unsurpassed by any other premium offering.”
Alexander Foster, MD
Alexander Foster, MDDavies Eye Center
“Every decade or so, a technology emerges which shifts the balance of our clinic and provides the next level of scientific achievement. The Light Adjustable Lens is the IOL I will have in my eyes, and we recommend it for every candidate in our practice.”
Steven Silverstein, MD
Steven Silverstein, MDSilverstein Eye Centers
“Patient satisfaction is through the roof! With the Light Adjustable Lens, patients can test drive their vision and I can fine tune it to meet their individual needs—in the same way that a fine suit can be custom tailored for just one person. There is simply nothing else like it.”
Kiper Nelson, MD
Kiper Nelson, MDSouthern Eye Center
“The Light Adjustable Lens is the best investment we’ve ever made. There are so many happy patients, and happy patients have no problem sharing their experience with others. We can barely keep up with the demand.”
Kelly Clayton, COO
Kelly Clayton, COORichens Eye Center
“If you want to have happy patients, offer the Light Adjustable Lens. The number of pa­tients referring friends and family for this technology far ex­ceeds anything I’ve ever seen. There’s no comparison.”
John Doane, MD
John Doane, MDDiscover Vision Centers
“We’re past the point of early adoption for the Light Adjustable Lens now. Practices that don’t participate will be left behind. If you want to have a thriving practice that offers the best technology, you simply have to offer this.”
John Vukich, MD
John Vukich, MDSummit Eye Care of Wisconsin

Adjust for Infinite Possibilities

The Light Adjustable Lens is a versatile premium lens that a growing number of surgeons are finding is customizable for many types of patients. Throughout the adjustment process, Light Adjustable Lens patients are engaged and participate in their care in a way other lenses can’t offer.

This truly customized approach has led to outcomes they and their doctors are excited about. Almost daily, we add to the list of clinics nationwide that are successfully integrating the Light Adjustable Lens into their workflow and finding that it is a worthwhile investment for their practices and their patients.

How the Light Adjustable Lens Works

The Light Adjustable Lens is implanted using a standard cataract procedure. Patients then experience their vision and surgeons can adjust the lens over a series of treatments to ensure each patient achieves vision that matches their lives. Each adjustment is a UV light treatment performed by the Light Delivery Device (LDD®) that corrects refractive error and dials in optimized vision.
Light from the RxSight LDD is directed by the surgeon to the Light Adjustable Lens.
Light from the RxSight LDD is directed by the surgeon to the Light Adjustable Lens.
Macromers in the path of the light are photopolymerized.
Macromers in the path of the light are photopolymerized.
Unpolymerized macromers move into the exposed area, causing precise shape and power change.
Unpolymerized macromers move into the exposed area, causing precise shape and power change.
The entire lens is exposed to light to polymerize all the remaining macromers.
The entire lens is exposed to light to polymerize all the remaining macromers.
The outcome is a precise change in the lens power to match the patient’s individual prescription.
The outcome is a precise change in the lens power to match the patient’s individual prescription.

Macromers/polymers are not visible in the lens, and graphic is used only as an illustration.

The Importance of ActivShield™ Technology

ActivShield is a UV protection layer built into the Light Adjustable Lens. Along with UV glasses, ActivShield helps prevent accidental sunlight exposure from changing the lens prior to the final lock-in treatment.

ActivShield UV Protector
Play Video

Don’t Get Left in the Dark

Discover More About the Light Adjustable Lens

Join us in changing the shape of cataract surgery; fill out the form below to receive our complete guide to the Light Adjustable Lens.

HCP Download
Light Adjustable Lens brochure cover
  1. Watanabe K, Negishi K, Kawai M, et al. Effect of experimentally induced astigmatism on functional, conventional, and low-contrast visual acuity. J Refract Surg. 2013;29(1):19-24.
  2. RxSight P160055: FDA Summary of Safety and Effectiveness Data. 2017.
  3. Sandoval HP, Donnenfeld ED, Kohnen T, et al. Modern laser in situ keratomileusis outcomes. J Cataract Refract Surg. 2016;42(8):1224-1234.
RxSight logo
Facebook-f Instagram Twitter Youtube Linkedin-in

Important Safety Information

Indications: The Light Adjustable Lens and Light Delivery Device system is indicated for the reduction of residual astigmatism to improve uncorrected visual acuity after removal of the cataractous natural lens by phacoemulsification and implantation of the intraocular lens in the capsular bag in adult patients:

  • With preexisting corneal astigmatism of ≥ 0.75 diopters
  • Without preexisting macular disease

The system also reduces the likelihood of clinically significant residual spherical refractive errors.

Contraindications: The Light Adjustable Lens is contraindicated in patients who are taking systemic medication that may increase sensitivity to ultraviolet (UV) light as the LDD treatment may lead to irreversible phototoxic damage to the eye; patients who are taking a systemic medication that is considered toxic to the retina (e.g., tamoxifen) as they may be at increased risk of retinal damage during LDD treatment; patients with a history of ocular herpes simplex virus due to the potential for reactivation from exposure to UV light; patients with nystagmus as they may not be able to maintain steady fixation during LDD treatment; and patients who are unwilling to comply with the postoperative regimen for adjustment and lock-in treatments and wearing of UV protective eyewear.

Warnings: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting an IOL in a patient with any of the conditions described in the Light Adjustable Lens and LDD Professional Use Information document. Caution should be used in patients with eyes unable to dilate to a pupil diameter of ≥ 7 mm to ensure that the edge of the Light Adjustable Lens can be visualized during LDD light treatments; patients who the doctor believes will be unable to maintain steady fixation that is necessary for centration of the LDD light treatment; and patients with sufficiently dense cataracts that preclude examination of the macula as patients with preexisting macular disease may be at increased risk for macular disease progression.

Precautions: The long-term effect on vision due to exposure to UV light that causes erythropsia (after LDD treatment) has not been determined. The implanted Light Adjustable Lens MUST undergo a minimum of 2 LDD treatments (1 adjustment procedure plus 1 lock-in treatment) beginning at least 17-21 days post-implantation. All clinical study outcomes were obtained using LDD power adjustments targeted to emmetropia post LDD treatments. The safety and performance of targeting to myopic or hyperopic outcomes have not been evaluated. The safety and effectiveness of the Light Adjustable Lens and LDD have not been substantiated in patients with preexisting ocular conditions and intraoperative complications.

Patients must be instructed to wear the RxSight-specified UV protective eyewear during all waking hours after Light Adjustable Lens implantation until 24 hours post final lock-in treatment. Unprotected exposure to UV light during this period can result in unpredictable changes to the Light Adjustable Lens, causing aberrated optics and blurred vision, which might necessitate explantation of the Light Adjustable Lens.

Adverse Events: The most common adverse events (AEs) reported in the randomized pivotal trial included cystoid macular edema (3 eyes, 0.7%), hypopyon (1 eye, 0.2%), and endophthalmitis (1 eye, 0.2%). The rates of AEs did not exceed the rates in the ISO historical control except for the category of secondary surgical interventions (SSI); 1.7% of eyes (7/410) in the Light Adjustable Lens group had an SSI (p < .05). AEs related to the UV light from the LDD include phototoxic retinal damage causing temporary loss of best spectacle corrected visual acuity (1 eye, 0.2%), persistent induced tritan color vision anomaly (2 eyes, 0.5%), persistent induced erythropsia (1 eye, 0.3%), reactivation of ocular herpes simplex Infection (1 eye, 0.3%), and persistent unanticipated significant increase in manifest refraction error (≥ 1.0 D cylinder or MRSE) (5 eyes, 1.3%).

Caution: Federal law restricts this device to sale by or on the order of a physician.

Click here for Instructions for Use

For clinical study data, please see the FDA Summary of Safety and Effectiveness.

©2023 RxSIGHT. All Rights Reserved. COM-1043 Rev. B

LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

The LAL provides optimized vision for patient satisfaction.2

LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

Since the LAL is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to potentially enhanced vision and patient satisfaction.

LAL patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The LAL offers LASIK-like accuracy in cataract surgery.2,3

92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).

Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.

The Light Adjustable Lens corrects down to 0.5 diopters of postoperative cylinder.

The LAL corrects down to 0.5 diopters of astigmatism, which is the lowest level approved to be treated.

The ability to treat 0.50 D of postoperative cylinder makes the Light Adjustable Lens the only IOL in the United States approved to correct this level of vision-altering astigmatism. Astigmatism of as little as 0.50 D can reduce visual acuity by one line, and the impact on dynamic, functional visual acuity and low-contrast acuity is even greater.1